Non-Small Cell Lung Cancer
Conditions
Brief summary
The main purpose of the study is to learn about the effectiveness and treatment sequence of lung cancer medicines. This study is performed outside of clinical trials in Norway in patients with metastatic non-small cell lung cancer. Non-small cell lung cancer is a group of lung cancers named for the kinds of cells found in the cancer and how the cells look under a microscope. Metastasis is when the cancer cells spread to other parts of the body. This study includes patient's data from the database who: * Are 18 years of age or older. * Are confirmed to have metastatic non-small cell lung cancer between 01 January 2009 and 31 December 2022. The study is based on data collection from 3 national health registries: * The Cancer Registry of Norway (CRN), * The Norwegian Patient Registry (NPR), * The Norwegian Drug Registry (NDR). Data from these registries will be linked at an individual patient level to create a single, unified dataset. The information collected includes: Diagnosis, cancer stage at diagnosis, date of diagnosis, birth year, type of medicinal treatment, date of treatment start and end, treating hospital, age, gender, etc.
Interventions
DRUGlorlatinib
As provided in real world practice
DRUGcrizotinib
As provided in real world practice
DRUGbrigatinib
As provided in real world practice
DRUGceritinib
As provided in real world practice
DRUGalectinib
As provided in real world practice
DRUGatezolizumab
As provided in real world practice
DRUGbevacizumab
As provided in real world practice
DRUGpaclitaxel
As provided in real world practice
DRUGcarboplatin
As provided in real world practice
DRUGdocetaxel
As provided in real world practice
DRUGerlotinib
As provided in real world practice
DRUGgefitinib
As provided in real world practice
DRUGafatinib
As provided in real world practice
DRUGdacomitinib
As provided in real world practice
DRUGosimertinib
As provided in real world practice
DRUGpembrolizumab
As provided in real world practice
DRUGnivolumab
As provided in real world practice
DRUGentrectinib
As provided in real world practice
Sponsors
Pfizer
Study design
Observational model
OTHER
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients ≥ 18 years old with histologically confirmed stage IIIb, IIIc, IVa, or IVb NSCLC at the time of diagnosis 2. Received their first NSCLC diagnosis (stage IIIb, IIIc, IVa, or IVb) between 01 January 2009, and latest available year
Exclusion criteria
1. Patients ≥ 18 years old with histologically confirmed stage IIIb, IIIc, IVa, or IVb NSCLC at the time of diagnosis who received radiation therapy with curative intent, defined as a radiation dose larger than 50gy 2. If the data include patients diagnosed after 2021, IIIb patients will be excluded due to changes in the guideline. The updated guidelines for 2022 recommends that patients diagnosed with stage IIIb who have surgery with the intent to cure should not have ''curative'' radiation (i.e.: it is not possible to exclude these from the population from 2022).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Duration of Treatment of Anti-cancer Drugs | From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | The duration of treatment of anti-cancer drugs was calculated as median time to treatment (mToT) for first line treatment and the median total ToT for all treatment lines (mTToT) for the anticancer therapies for EGFR+, ALK+ and ROS1+ and was presented in this outcome measure. mToT measured the time on the treatment participants receive as first line treatment, measuring the time from they start the treatment until they stop the first line treatment (or end of follow up), using the Kaplan Meier estimator. mTToT measured the time on all treatment - from the time they start first line treatment, until the point they stop their last treatment line (or end of follow up), using the Kaplan Meier estimator. |
| Number of Participants Classified According to Treatments of Anti-cancer Drugs | From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | Number of participants were classified and reported according to the Anti-cancer drugs received during first-line, second-line and third-line treatment after diagnosis of NSCLC. |
| Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | Number of participants were classified and reported according to the treatment lines received including first-line, second-line and third-line treatment after diagnosis of NSCLC. |
| Overall Survival (OS) | From treatment initiation (1-Jan-2015) to date of death (until 31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | OS was defined as time from treatment initiation of anticancer therapy to date of death due to any cause. Analysis was performed by Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study | The percentage of participants classified according to the disease stages as 3B, 3C, 4A and 4B at the time of diagnosis were reported in this outcome measure. Cancer stages were classified based on tumor size (T), metastasis to nearby lymph nodes (LN) \[N\] and distant metastasis (M). Stages were 3B, 3C, 4A and 4B. Stage 3B (T1N3M0, T2N3M0, T3N3M0 and T4N2M0). Stage 3C (T3N3M0, T4N3M0), Stage 4A (anyT, anyM and M1a/M1b), Stage 4B (anyT, anyM and M1c). where T1=\<3 cm; T2= 3 to \<5 cm; T3= 5 to \<7 cm; T4= \>7cm. N0=not spread to LN; N1=spread to 1 to 3; N2=spread to 4 to 9; N3=spread \>10 axillary LN. M0= no metastasis; M1a= cancer has spread to other lung; M1b= cancer has as a single tumor outside of the chest, such as to a distant lymph node or an organ such as the liver, bones, or brain; M1c= cancer has spread as more than one tumor outside the chest, such as to distant lymph nodes and/or to other organs such as the liver, bones, or brain. |
| Number of Participants Classified as Per Specific Norwegian Health Regions | At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study | Number of participants classified according to the Norwegian health regions were reported in this outcome measure. |
| Percentage of Participants Classified According to the NSCLC Histopathological Subtype | At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study | Percentage of participants classified according to the NSCLC histopathological subtype viz adenocarcinoma, non-small cell carcinoma, large cell neuroendocrine carcinoma were reported in this outcome measure. |
| Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | Number of participants classified according to the selected administered non-cancer drugs (anticoagulants and statins) were reported in this outcome measure. |
| Number of Packs Dispensed at the Time of Dispensing | From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study | Number of packs dispensed to participants at the time of dispensing were reported in this outcome measure. |
Countries
Norway
Participant flow
Recruitment details
Data of eligible participants with non-small cell lung cancer (NSCLC) with age greater than (\>) 18 years at the time of initiating anticancer therapy was collected retrospectively from the 3 national registries: Cancer Registry of Norway (CRN), the Norwegian Drug Registry (NDR) and the Norwegian Patient Registry (NPR) between 1-Jan-2015, and 31-Dec-2022 (maximum up to 96 months). The study was conducted in Norway.
Pre-assignment details
Available data was evaluated as per the study objectives, from 23-Jun-2023 to 23-Jan-2024 (approximately 7 months) in this retrospective observational study.
Participants by arm
| Arm | Count |
|---|---|
| Biomarker Cohort Participants with NSCLC who were positive for biomarkers (EGFR or ALK or ROS1) and were identified from CRN, NDR or NPR between 01-Jan-2015 to 31-Dec-2022 were included in this retrospective observational study. | 618 |
| Non-biomarker Cohort Participants with NSCLC with unknown biomarker status (EGFR or ALK or ROS1) and were identified from CRN, NDR or NPR between 01-Jan-2015 to 31-Dec-2022 were included in this retrospective observational study. | 4,661 |
| Total | 5,279 |
Baseline characteristics
| Characteristic | Biomarker Cohort | Non-biomarker Cohort | Total |
|---|---|---|---|
| Age, Continuous | 67.1 Years STANDARD_DEVIATION 13 | 70.7 Years STANDARD_DEVIATION 9.7 | 70.2 Years STANDARD_DEVIATION 10.2 |
| Race and Ethnicity Not Collected | — | — | 0 Participants |
| Sex: Female, Male Female | 385 Participants | 2158 Participants | 2543 Participants |
| Sex: Female, Male Male | 233 Participants | 2503 Participants | 2736 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 364 / 618 | 3,780 / 4,661 |
| other Total, other adverse events | 0 / 0 | 0 / 0 |
| serious Total, serious adverse events | 0 / 0 | 0 / 0 |
Outcome results
Primary
Duration of Treatment of Anti-cancer Drugs
The duration of treatment of anti-cancer drugs was calculated as median time to treatment (mToT) for first line treatment and the median total ToT for all treatment lines (mTToT) for the anticancer therapies for EGFR+, ALK+ and ROS1+ and was presented in this outcome measure. mToT measured the time on the treatment participants receive as first line treatment, measuring the time from they start the treatment until they stop the first line treatment (or end of follow up), using the Kaplan Meier estimator. mTToT measured the time on all treatment - from the time they start first line treatment, until the point they stop their last treatment line (or end of follow up), using the Kaplan Meier estimator.
Time frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure and Number Analyzed signifies participants evaluable for specified rows.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | EGFR+ participants receiving other TKI: mTToT | 15.8 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | EGFR+ participants receiving osimertinib: mToT | 11 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | EGFR+ participants receiving osimertinib: mTToT | 14 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | EGFR+ participants receiving other TKI: mToT | 9.4 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving alectinib: mToT | 20 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving alectinib: mTToT | 28 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving brigatinib: mToT | 11 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving brigatinib: mTToT | 16 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving crizotinib: mToT | 7 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ALK+ participants receiving crizotinib: mTToT | 19 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ROS1+ participants receiving crizotinib: mToT | 5 Months |
| Biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | ROS1+ participants receiving crizotinib: mTToT | 18 Months |
| Non-biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | Non-biomarker participants receiving crizotinib: mToT | 3 Months |
| Non-biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | Non-biomarker participants receiving crizotinib: mTToT | 8.1 Months |
| Non-biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | Non-biomarker participants receiving erlotinib: mToT | 0.9 Months |
| Non-biomarker Cohort | Duration of Treatment of Anti-cancer Drugs | Non-biomarker participants receiving erlotinib: mTToT | 6.3 Months |
Primary
Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs
Number of participants were classified and reported according to the treatment lines received including first-line, second-line and third-line treatment after diagnosis of NSCLC.
Time frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number Analyzed signifies number evaluable for specified rows. All participants under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | ALK+: first line treatment | 115 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | ALK+: second line treatment | 51 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | ALK+: third line treatment | 20 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | ROS1+: first line treatment | 22 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | ROS1+: second line treatment | 6 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | EGFR+: first line treatment | 335 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | EGFR+: second line treatment | 139 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | EGFR+: third line treatment | 44 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | Non-biomarker: second line treatment | 58 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | Non-biomarker: third line treatment | 9 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatment Lines of Anti-cancer Drugs | Non-biomarker: first line treatment | 2589 Participants |
Primary
Number of Participants Classified According to Treatments of Anti-cancer Drugs
Number of participants were classified and reported according to the Anti-cancer drugs received during first-line, second-line and third-line treatment after diagnosis of NSCLC.
Time frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure; Number Analyzed signifies participants evaluable for specified rows. All participants under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving osimertinib in second line | 25 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving afatinib in second line | 22 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving brigatinib in first line | 21 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving alecitinib in second line | 14 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving crizotinib in second line | 4 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving other drugs in second line | 21 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving lorlatinib in third line | 6 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving alectinib in third line | 4 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving crizotinib in third line | 2 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving other drugs in third line | 8 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ROS1+ participants receiving IO/ChT in first line | 13 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ROS1+ participants receiving crizotinib in first line | 5 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving osimertinib in first line | 104 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving gefitinib in first line | 86 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving erlotinib in first line | 50 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving crizotinib in first line | 2 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving other drugs in first line | 93 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving IO and/or ChT in second line | 53 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving erlotinib in second line | 19 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving other drugs in second line | 20 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving IO and/or ChT in third line | 17 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving osimertinib in third line | 13 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving erlotinib in third line | 3 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | EGFR+ participants receiving other drugs in third line | 11 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving alecitinib in first line | 55 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving crizotinib in first line | 29 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving other drugs in first line | 10 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ALK+ participants receiving lorlatinib in second line | 12 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ROS1+ participants receiving other drugs in first line | 4 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ROS1+ participants receiving crizotinib in second line | 2 Participants |
| Biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | ROS1+ participants receiving other drugs in second line | 4 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving crizotinib in first line | 23 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving erlotinib in first line | 26 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving IO/ChT in first line | 2540 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving crizotinib in second line | 7 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving erlotinib in second line | 13 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving IO/ChT in second line | 22 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving other drugs in second line | 16 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving erlotinib in third line | 1 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to Treatments of Anti-cancer Drugs | Non-biomarker participants receiving other drugs in third line | 8 Participants |
Primary
Overall Survival (OS)
OS was defined as time from treatment initiation of anticancer therapy to date of death due to any cause. Analysis was performed by Kaplan-Meier method.
Time frame: From treatment initiation (1-Jan-2015) to date of death (until 31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number Analyzed signifies number evaluable for specified rows. All participants under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| Biomarker Cohort | Overall Survival (OS) | ROS+ participants: 2015-2019 | NA Months |
| Biomarker Cohort | Overall Survival (OS) | All participants: 2015-2019 | 19 Months |
| Biomarker Cohort | Overall Survival (OS) | ALK+ participants: 2020-2022 | NA Months |
| Biomarker Cohort | Overall Survival (OS) | ROS+ participants: 2020-2022 | NA Months |
| Biomarker Cohort | Overall Survival (OS) | All participants: 2020-2022 | 23 Months |
| Biomarker Cohort | Overall Survival (OS) | EGFR+ participants: 2015-2019 | 18 Months |
| Biomarker Cohort | Overall Survival (OS) | EGFR+ participants: 2020-2022 | 23 Months |
| Biomarker Cohort | Overall Survival (OS) | ALK+ participants: 2015-2019 | 24 Months |
| Non-biomarker Cohort | Overall Survival (OS) | All participants: 2015-2019 | 5 Months |
| Non-biomarker Cohort | Overall Survival (OS) | All participants: 2020-2022 | 7 Months |
Secondary
Number of Packs Dispensed at the Time of Dispensing
Number of packs dispensed to participants at the time of dispensing were reported in this outcome measure.
Time frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study. Here, Number of Participants Analyzed signifies participants evaluable for this outcome measure and Number Analyzed signifies participants evaluable for specified rows. All participants under Number of Participants Analyzed contributed data to the table but may not have evaluable data for every row.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 3 packs at fourth dispensation | 3 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 4 packs or more at first dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 4 packs or more at second dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 4 packs or more at third dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 4 packs or more at fourth dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 1 pack at first dispensation | 131 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 1 pack at second dispensation | 102 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 1 pack at third dispensation | 86 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 1 pack at fourth dispensation | 74 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 2 packs at fourth dispensation | 21 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 3 packs at first dispensation | 5 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 3 packs at second dispensation | 6 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 3 packs at third dispensation | 9 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 3 packs at fourth dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 4 packs or more at first dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 4 packs or more at second dispensation | 1 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 4 packs or more at third dispensation | 1 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 4 packs or more at fourth dispensation | 1 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at first dispensation | 65 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at second dispensation | 61 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at third dispensation | 57 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at fourth dispensation | 44 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at first dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at second dispensation | 3 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at third dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at fourth dispensation | 9 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at first dispensation | 3 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at second dispensation | 5 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at third dispensation | 5 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at fourth dispensation | 2 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at first dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at second dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at third dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at fourth dispensation | 0 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at first dispensation | 41 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at second dispensation | 31 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at fourth dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at first dispensation | 8 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at second dispensation | 7 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at third dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at fourth dispensation | 7 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at third dispensation | 21 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at fourth dispensation | 19 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at first dispensation | 2 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at second dispensation | 4 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at third dispensation | 6 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 1 pack at first dispensation | 71 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 1 pack at second dispensation | 64 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 1 pack at third dispensation | 51 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 1 pack at fourth dispensation | 49 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 2 packs at first dispensation | 1 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 2 packs at second dispensation | 3 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 2 packs at third dispensation | 9 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 2 packs at fourth dispensation | 8 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 3 packs at first dispensation | 1 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 3 packs at second dispensation | 2 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Alectinib: 3 packs at third dispensation | 2 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 2 packs at first dispensation | 6 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 2 packs at second dispensation | 17 Participants |
| Biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Osimertinib: 2 packs at third dispensation | 18 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: <1 pack at first dispensation | 14 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: <1 pack at second dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: <1 pack at third dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at second dispensation | 2 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at third dispensation | 15 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at first dispensation | 28 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at fourth dispensation | 10 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at third dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at first dispensation | 2 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at third dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at second dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: <1 pack at fourth dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at third dispensation | 2 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at fourth dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at first dispensation | 23 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 1 pack at second dispensation | 24 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at second dispensation | 15 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at first dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at third dispensation | 7 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at second dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 1 pack at fourth dispensation | 5 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at second dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at first dispensation | 2 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 2 packs at fourth dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at second dispensation | 3 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at third dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at third dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at fourth dispensation | 0 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 2 packs at fourth dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 4 packs or more at fourth dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Erlotinib: 3 packs at first dispensation | 1 Participants |
| Non-biomarker Cohort | Number of Packs Dispensed at the Time of Dispensing | Crizotinib: 3 packs at first dispensation | 0 Participants |
Secondary
Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs
Number of participants classified according to the selected administered non-cancer drugs (anticoagulants and statins) were reported in this outcome measure.
Time frame: From treatment initiation (1-Jan-2015) to end of follow-up (31-Dec-2022) [maximum up to 96 months]; retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Enoxaparin | 79 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Combinations, acetylsalicylic acid | 0 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dabigatran etexilate | 2 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Apixaban | 107 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Warfarin | 1 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Heparin | 6 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dalteparin | 99 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Clopidogrel | 12 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Acetylsalicylic acid | 91 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dipyridamole | 5 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Prasugrel | 1 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Ticagrelor | 2 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Rivaroxaban | 14 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Edoxaban | 15 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Fondaparinux | 0 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Simvastatin | 47 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Pravastatin | 10 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Fluvastatin | 1 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Atorvastatin | 97 Participants |
| Biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Rosuvastatin | 11 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Fondaparinux | 2 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Enoxaparin | 523 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Ticagrelor | 14 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dipyridamole | 41 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Combinations, acetylsalicylic acid | 48 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Fluvastatin | 7 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dabigatran etexilate | 28 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Rivaroxaban | 103 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Prasugrel | 8 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Apixaban | 498 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Simvastatin | 375 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Warfarin | 33 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Rosuvastatin | 59 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Heparin | 42 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Pravastatin | 34 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Dalteparin | 659 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Edoxaban | 55 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Clopidogrel | 139 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Statin: Atorvastatin | 646 Participants |
| Non-biomarker Cohort | Number of Participants Classified According to the Selected Participant Administered Non-Cancer Drugs | Anticoagulant: Acetylsalicylic acid | 843 Participants |
Secondary
Number of Participants Classified as Per Specific Norwegian Health Regions
Number of participants classified according to the Norwegian health regions were reported in this outcome measure.
Time frame: At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Northern Norway Regional Health Authority | 44 Participants |
| Biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Western Norway Regional Health Authority | 156 Participants |
| Biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Central Norway Regional Health Authority | 70 Participants |
| Biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Unknown | 7 Participants |
| Biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | South-East Norway Regional Health Authority | 341 Participants |
| Non-biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Unknown | 26 Participants |
| Non-biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Central Norway Regional Health Authority | 665 Participants |
| Non-biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Northern Norway Regional Health Authority | 488 Participants |
| Non-biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | South-East Norway Regional Health Authority | 2427 Participants |
| Non-biomarker Cohort | Number of Participants Classified as Per Specific Norwegian Health Regions | Western Norway Regional Health Authority | 1055 Participants |
Secondary
Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis
The percentage of participants classified according to the disease stages as 3B, 3C, 4A and 4B at the time of diagnosis were reported in this outcome measure. Cancer stages were classified based on tumor size (T), metastasis to nearby lymph nodes (LN) \[N\] and distant metastasis (M). Stages were 3B, 3C, 4A and 4B. Stage 3B (T1N3M0, T2N3M0, T3N3M0 and T4N2M0). Stage 3C (T3N3M0, T4N3M0), Stage 4A (anyT, anyM and M1a/M1b), Stage 4B (anyT, anyM and M1c). where T1=\<3 cm; T2= 3 to \<5 cm; T3= 5 to \<7 cm; T4= \>7cm. N0=not spread to LN; N1=spread to 1 to 3; N2=spread to 4 to 9; N3=spread \>10 axillary LN. M0= no metastasis; M1a= cancer has spread to other lung; M1b= cancer has as a single tumor outside of the chest, such as to a distant lymph node or an organ such as the liver, bones, or brain; M1c= cancer has spread as more than one tumor outside the chest, such as to distant lymph nodes and/or to other organs such as the liver, bones, or brain.
Time frame: At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 4A | 36.2 Percentage of participants |
| Biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 3B | 3.5 Percentage of participants |
| Biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 3C | 1.6 Percentage of participants |
| Biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 4B | 58.6 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 3B | 5.6 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 4A | 36.2 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 4B | 55.1 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the Disease Stage at the Time of Diagnosis | Stage 3C | 3.1 Percentage of participants |
Secondary
Percentage of Participants Classified According to the NSCLC Histopathological Subtype
Percentage of participants classified according to the NSCLC histopathological subtype viz adenocarcinoma, non-small cell carcinoma, large cell neuroendocrine carcinoma were reported in this outcome measure.
Time frame: At time of diagnosis (up to 3 months prior to treatment initiation); retrospective data was retrieved and analyzed during 7 months of this observational study
Population: Analysis population included all eligible participants whose data was retrieved and observed in this retrospective observational study.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Adenocarcinoma | 94.7 Percentage of participants |
| Biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Non-small cell carcinoma | 5.0 Percentage of participants |
| Biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Large cell neuroendocrine carcinoma | 0.3 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Adenocarcinoma | 80.8 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Non-small cell carcinoma | 16.8 Percentage of participants |
| Non-biomarker Cohort | Percentage of Participants Classified According to the NSCLC Histopathological Subtype | Large cell neuroendocrine carcinoma | 2.4 Percentage of participants |